Lumibird: 2022 FIRST-HALF REVENUES OF €84M (+11%)
25 Juli 2022 - 5:45PM
Lumibird: 2022 FIRST-HALF REVENUES OF €84M (+11%)
Lannion, July 25, 2022 – 5:45pm
2022 FIRST-HALF REVENUES OF €84M
(+11%)
The LUMIBIRD Group, the European leader
for laser technologies, is reporting sustained growth, with
revenues up +10% in the second quarter of 2022 and +11% for the
first half of the year. As a significant percentage of sales are
recorded in dollars, the increase on a like-for-like basis and at
constant exchange rates is slightly lower, with +9% for the first
half of 2022.
Consolidated revenues
(unaudited)
Revenues (€m) |
2022 |
2021 |
Change |
First quarter |
38.0 |
33.8 |
+12% |
Second quarter |
46.0 |
41.7 |
+10% |
First half |
84.0 |
75.5 |
+11% |
of which |
|
|
|
Photonics |
38.6 |
34.7 |
+11% |
Medical |
45.4 |
40.8 |
+11% |
The LUMIBIRD Group’s consolidated revenues came
to €84.0m at June 30, 2022, up 11% (9% like-for-like and at
constant exchange rates). This growth is split equally across the
Photonics and Medical divisions. The Group is organized to produce
against a backdrop of the disruption affecting supply chains
globally. However, across the various business segments, this
disruption may result in deliveries being deferred from one quarter
to another.
This is notably the case for the
Photonics division, with contrasting levels of
growth that do not necessarily reflect the overall trend. The
Industrial and Scientific business lines show first-half growth of
+2% (to €17.4m), while the Lidar business is up +48% to €11.0m,
with an increase in sales for both Lidar and OEM systems. The
Defense / Space business is stable for the first half of the year
(+1% to €10.2m), with a relatively significant base effect due to a
particularly high second quarter in 2021. The new subsidiary
Lumibird Photonics Sweden (former Saab), consolidated since May 31,
2022, made a still marginal contribution to business (€0.36m).
The Medical division, with
first-half growth of +11% (€45.4m), is benefiting from a catch-up
with deliveries from the order book at end-March and an
acceleration in sales, particularly in the United States, where the
strengthening of the sales teams and the extension of the product
range are reflected in very positive trends.
LUMIBIRD is looking ahead to the second half of
the year with an extremely sustained order book, for its Photonics
and Medical activities. Its ability to build on these positive
commercial trends is still linked to the production and delivery
contingencies in a context of pressure on supply chains.
The Group is confirming its targets for 2023
reported revenues of over €250m, driven by organic and external
growth, with its EBIDTA/revenue ratio to continue increasing within
a 20%-25% range.
Next date:
2022 half-year earnings on September 22, 2022
(after close of trading)
LUMIBIRD is one of the world's leading
specialists in lasers. With 50 years of experience and a mastering
of solid state laser, laser diodes and fiber laser technologies,
the Group designs, manufactures and markets high performance lasers
for scientific (laboratories and universities), industrial
(manufacturing, defense, Lidar sensors) and medical (ophthalmology,
ultrasound diagnostic) markets.
Born from the combination of Keopsys Group with
Quantel in October 2017, LUMIBIRD has more than 940 employees and
over €162 million of consolidated revenues in 2021 and is
present in Europe, America and Asia.
LUMIBIRD shares are listed on the
Euronext Paris B Compartment. FR0000038242 –
LBIRD www.lumibird.comSince
2022, LUMIBIRD is part of
Euronext Tech Leaders
Contacts
LUMIBIRDMarc Le FlohicChairman and CEOTel. +33(0) 1 69 29 17
00info@lumibird.com |
LUMIBIRDAude Nomblot-GourhandSecretary General – CFOTel. +33(0) 1
69 29 17 00info@lumibird.com |
CalyptusMathieu CalleuxInvestors RelationsTel. +33(0) 1 53 65 37
91lumibird@calyptus.net |
- 220725LumibirdCAS12022_EN
Lumibird (EU:LBIRD)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Lumibird (EU:LBIRD)
Historical Stock Chart
Von Apr 2023 bis Apr 2024